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OA (0.66 ≥ r ≥ 0.40) as measured by KL scores. The MRI-Atlas measure-
ments also correlated with the medial JSN OARSI scores and with the JSW
(r ≤ 0.48). Even with this small sample size the results are encouraging, and
indicate the potential of atlas-based measurements for diagnosing, staging
and evaluating progression of OA.
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FOUR CLEAVAGE SITES INVOLVING OPTICIN AND METALLOPROTEINASES.
NEW FRAGMENTS AS BIOMARKERS IN OA?
L. Tío1, N. Garcia-Giralt1, P. Benito2, J.P. Pelletier3, J.M. Pelletier3,
J. Monfort2
1IMIM. PRBB, Barcelona, Spain; 2IMAS, Hosp. del Mar, Barcelona, Spain;
3Osteoarthritis Res. Unit. Univ. of Montreal, Montreal, QC, Canada
Purpose: Opticin is a glycoprotein belonging to small leucine rich
proteoglicans (SLRPs) family. These proteoglicans are part of the cartilage
extracellular matrix and are associated with the collagen ﬁbrils, regulating
ﬁbril morphology, spacing, and organization. In a previous work we studied
the opticin degradation by different MMPs and ADAMTS involved in OA
pathology, and we observed that digestion patterns were different not only
between the several proteases but also between the proteoglicans extract
obtained from OA cartilage and normal one. This work showed us the be-
havior of this glycoprotein in an environment close to the one found in vivo
but it was not suitable to perform sequencing of the fragments generated.
In order to complete the knowledge of these digestions and to identify
the fragments generated, we decided to study the digestion with human
recombinant opticin. The digestions were performed with the proteases
deﬁned to be the mainly responsible for the development of the OA.
Methods: Recombinant human opticin c-terminal tagged with MYC/DDK
was digested with MMP 1, -2, -3, -7, -8, -9, 13 and ADAMTS-4, -5, at several
incubation times, in a range between 15 minutes and 24 hours. The prote-
olytic activities were analyzed by western blot using both anti-opticin and
anti-MYC antibody. In the case of the opticin digestion with MMP-2 and
MMP-7, they were blot and subsequently transferred to a PVDF membrane.
Finally, the fragments were isolated to perform Edman sequencing.
Results: The metalloproteinases generated different opticin digestion pat-
terns, and we can join up the fragments into four different sizes: 28, 30, 32
and 37 KDa. Each digestion presents at least 2 of these fragments although
with different intensity, depending on the incubation time. These show us
that the digestions are performed in a stepped way and not amioacid by
aminoacid. A previous work has studied the digestion of bovine opticin
by human MMP-13, and described a fragment of 24 kDa generated by the
cleavage between Leu116 and Leu117. If we take into account that the size
of the tag of the human opticin is 3’8 KDa, we can hypothesize that the
fragment of 28 KDa and the 24KDa fragment previously described are the
same. Now we have described three more cleavage sites in opticin, and the
fact that these sites seem to be common for different metalloproteinases.
To study more in detail these fragments, we decided to focus in the study
of the opticin digestion by MMP-2 and MMP-7 for two reasons: on one
hand, they are the ones that digest faster the opticin so they could have
more implication in the degradation of these proteoglycans; and on the
other hand each one produces two representative of the fragments (MMP-2
generates fragments of 32 and 30 KDa and MMP-7 of 37 and 28 KDa). The
generation of these fragments will allow us to sequence the three new
cleavages sites, as well as to conﬁrm the one previously described.
The study of the opticin digestion was performed with two different
antibodies (anti-opticin and anti-MYC). Both antibodies detect the full
opticin, and its digestion can be followed till almost the disappearance of
the band, but only with the anti-MYC antibody the fragments could be
detected. This shows us that, although the opticin antibody is a polyclonal
one, non isoform detects the fragments obtained with the digestion. In a
previous work the digestions were performed with a proteoglican extract
and few fragments could be detected. This study indicated us that the
lack of digestion fragments could be due to lack on the detection and not
because they are not generated.
Conclusions: The digestions of opticin by several proteases yield four
different fragments. Three of them are new cleavages sites for opticin, and
the fourth seems to agree to a one already described. With these data we
try to give a clue of the consensus cleaving sites of metalloproteinases as
well as describing potentials biomarkers for OA. Furthermore, we ﬁnd out
that almost none of the fragments of digestion could be detect with an
anti-opticin polyclonal antibody. This result should be take into account in
future works studying protein degradation.
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A NOVEL BIOCHEMICAL MARKER OF MMP-DERIVED TYPE II COLLAGEN
DEGRADATION FOR JOINT DEGENERATIVE DISEASES, CIIM, IS
CORRELATED TO CARTILAGE VOLUME
A.-C. Bay-Jensen1, I. Byrjalsen1, J. Wang2, Q. Zheng2, E. Dam1, P. Qvist1,
M.A. Karsdal1
1Nordic BioSci. A/S, Herlev, Denmark; 2Nordic BioSci. China, Beijing, China
Purpose: Joint degenerative diseases are characterized as progressive loss
of articular cartilage. Cartilage matrix molecules are broken down by
proteases, such as metalloproteinases (MMPs), in this process and protein
fragments are released to the circulation. The level of these fragments can
be measured and used as biomarkers for disease stages or progression.
Type II collagen is the primary cartilage matrix protein and different
MMP-generated fragments have been identiﬁed in body ﬂuids. We target
one of such fragment in the development of a urine biomarker assay.
Methods: Human type II collagen was cleaved with MMP9 in vitro and
analyzed on mass spectrometry. A neoepitope was identiﬁed by Mascot
database search. Monoclonal antibodies were raised against the neoepitope
and a competitive EIA assay was developed: the CIIM assay. The validated
assay was used to measure the level of the type II fragment in urine of
a normal population. Cartilage volume of the knee was measured in 130
individuals by MRI.
Results: The developed immune-assay of CIIM showed good technical
performance and the release of the fragment could be completely inhibited
by MMP inhibitor GM6001, but not by cysteine protease inhibitor E64.
Furthermore the neoepitope could be immune-localized to OA pathological
features in cartilage retrieved from OA patients. A high level of CIIM
was measured in synovial ﬂuid and as well as in urine of individuals
from the MR cohort. The urinary level was signiﬁcantly higher in older
women compared to younger women. Furthermore, low cartilage volume,
measured by MRI, was correlated to high urinary levels of CIIM (p<0.05).
Conclusions: We developed and validated a novel biomarker assay for
MMP-derived type II collagen degradation - CIIM. We have within this
study showed that CIIM was indeed derived from MMP activity and that it
was generated at OA relevant sites in in situ OA cartilage samples. We also
showed that the markers was related to cartilage volume in knees.
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LARGE-SCALE AND BROAD-SPECTRUM BIOCHEMICAL MARKER ANALYSIS:
CHALLENGES AND CHOICES
W.E. van Spil1, N.W. Jansen1, J.W. Bijlsma1, J. DeGroot2, P.M. Welsing1,
F.P. Lafeber1
1Rheumatology & Clinical Immunology, Univ. Med. Ctr. Utrecht, Utrecht,
Netherlands; 2Business Unit BioSci., TNO Quality of Life, Zeist, Netherlands
Purpose: Osteoarthritis (OA) is currently regarded as a complex joint
disease; multiple articular and peri-articular structures being involved,
probably in a variable sequence and dominance between individuals.
However, current literature on biochemical OA markers mainly concerns
small-scale and small-spectrum studies and is thereby discordant with this
view. Instead, large-scale and broad-spectrum biochemical marker assess-
ment is preferable. Large-scale assessment might be regarded unfeasible
because of complex logistics, high ﬁnancial burden, and the increased
chance of inducing technical variability. This publication analyzes the chal-
lenges and choices of such a large-scale and broad-spectrum biochemical
marker assessment.
Methods: Eleven biochemical markers were assessed in urine and serum
samples of 1002 participants (Cohort Hip and Cohort Knee; CHECK)
by means of ELISA and RIA in a regular laboratory and commercially-
independent setting. The spectrum of biochemical markers consisted of
markers for cartilage, bone and synovial tissue metabolism and/or cellular
activity. The assessment was necessarily performed by multiple technicians,
in multiple assay plates, and during multiple days. Therefore, speciﬁc at-
tention to minimizing technically-induced variability was vital. In addition
to evaluation of several technical aspects, reliability of single instead of
multiple assessments per sample was evaluated. A standard sample was
repeatedly included in all assay plates throughout the assessment period
to quantify technically-induced variability (3 levels: within plates, within
all plates on a day, in all plates throughout the assessment period) and
evaluate adjustment for between-plate variability.
Results: The additional variation that was introduced by single instead of
S66 Poster Presentations / Osteoarthritis and Cartilage 18, Supplement 2 (2010) S45–S256
multiple sample assessments was limited and considered acceptable in the
context of logistics, scarcity of samples, and costs (triplicate assessment in
a subset of samples showed high correlation between biochemical marker
concentrations in the ﬁrst sample and the mean concentration in triplets; rs
0.841 - 0.996, P 0.000). Of the 11,000 assessments that were performed, 27
and 19 assessments showed concentrations that were below and above the
standard curve, respectively. Re-assessment in adjusted dilutions induced
(unpredictable) non-linear dilution effects and was considered inappro-
priate. Instead, artiﬁcial concentrations (0.8×minimum, 1.2×maximum
concentration) were used. Technically-induced variability increased stepwise
between the 3 levels (intra-plate<within day<total), but not statistically
signiﬁcantly. Correction for between-plate variability on the basis of compar-
ison of the standard sample assessment between assay plates decreased the
mean sum of squared differences between plates by a factor 1.5 (mean; SD
0.9). Three of the 11 biomarkers showed unanticipated results. One could be
re-assessed successfully, the other 2 remained unsolved, despite thorough
analyses in consultancy with the manufacturer.
Conclusions: Large-scale and broad-spectrum biochemical marker assess-
ment poses speciﬁc challenges. However, this study shows that large-scale
assessment was feasible for the vast majority of the studied biochemical
markers.
This study was funded by CHECK (Cohort Hip & Cohort Knee), an initiative
of the Dutch Arthritis Association.
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IMPACT OF CRYOPRESERVATION ON SERUM CONCENTRATION OF
BIOMARKERS MMP-7, TIMP-1, VEGF AND VEGF-R2 IN BIOBANK
K. Kisand1, K. Alnek1, J. Krjukova1, I. Kerna2, J. Kumm2, H. Jonsson3,
A.O. Tamm2
1Univ. of Tartu, Dept. of Immunology, Tartu, Estonia; 2Univ. of Tartu, Dept. of
Internal Med., Tartu, Estonia; 3Univ. of Iceland, Dept. of Rheumatology,
Reykjavik, Iceland
Purpose: In longitudinal studies like in osteoarthritis, serum samples are
collected over time, freezed (at-20°C) or deep-freezed (at -75°C or more),
and then simultaneously analyzed in order to minimize inter-assay vari-
ability. Unfortunately not much information has been published about the
impact of freezing and storage duration on biomarkers. In this study, we
investigated whether repeated freeze-thaw cycles or duration and temper-
ature of cryopreservation have an effect on the concentration of MMP-7,
TIMP-1, VEGF and VEGF-R2 measured in serum by ELISA.
Methods: Concentrations of biomarkers were measured by ELISA (R&D)
in the sera of patients with rheumatoid arthritis. To test stability, the
samples were frozen and thawed up to 6 times (0, 1, 3 and 6). Impact
of storage time/temperature was investigated using accelerated stability
testing protocol keeping samples at +4°C, +20°C, +30°C and +40°C up to 3
weeks. The stability for storage at -20°C and at -75°C was calculated using
Arrhenius equation (Kenis, G. et al., 2002) and the stability was expressed
as the period of time preserving at least 90% of the initial level of the
biomarker.
Results: One thawing cycle did not change signiﬁcantly concentration of
MMP-7 and VEGF-R2 measured by ELISA. But the level of these biomarkers
increased 20-24% after repeated thawing (3 or more cycles). The average
concentration of TIMP-1 decreased less than 13% even after 6 cycles of
thawing/freezing, but remarkable heterogeneity in deviation (increasing
or decreasing) from initial level was seen between individual sera. The
decrease in VEGF concentration (average 67%, from 30 to 95%) was very
remarkable even already after the ﬁrst thawing/freezing cycle.
The results of accelerated aging experiments were used to calculate the
liable concentration changes in cryopreservation of investigated biomark-
ers. According to Arrhenius’ calculation MMP-7 showed excellent stability
(at least 11 years at -20°C and several hundreds of years at -75°C !).
TIMP-1 keeps 90% of initial concentration at -20°C within one month and
10 months at -75°C. VEGF- R2 was more stable than VEGF and preserved at
-20°C within three months and at -75°C - 32 years (VEGF - one month and
4 months, respectively).
Conclusions: The conditions of storage of human sera in biobank should
be taken into account in the interpretation of the concentration of MMP-7,
TIMP-1, VEGF or VEGF-R2. Temperature -20 °C is not suitable for prolonged
storage of investigated biomarkers, except MMP-7.
VEGF-R2 and MMP-7 can be assessed in serum samples kept at -75 °C for
several decades. Repeated freezing of sera is not recommended as it may
increase the measured level of these biomarkers.
Assessment of TIMP-1 should be done within 10 months of storage at -75
°C. VEGF is not marker to test in cryopreserved sera as it is not stable at
thawing/freezing.
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VALIDATION OF BLOOD BIOMARKERS IN KNEE OSTEOARTHRITIS
Y.-M. Pers1,2, S. Fabre1, F. Djouad2, I. Duroux-Richard2, F. Apparailly2,
D. Noel2, C. Jorgensen1,2
1Unité Thérapeutique Clinique des Maladies Ostéoarticulaires, Montpellier,
France; 2INSERM U844, Montpellier, France
Purpose: In osteoarthritis (OA), many studies were focused in ﬁnding one
or more biomarkers reﬂecting the importance and the disease progression.
The aim of our study was to validate a number of these biomarkers.
Methods: Serum samples and fresh blood were obtained from 30 patients
with severe knee osteoarthritis (score of Kellgren/Lawrence K/L at least
3/4), 12 moderate knee OA patients (score of K/L less than 3) and 12
healthy donors as controls. We analyzed the systemic expression of CRP,
COMP, MMP-1 and MMP-3, osteocalcin, OPG, and CTX-I in the 3 groups
of patients by ELISA technique. Statistical analysis used the nonparametric
Wilcoxon test.
Results: OA patients had a mean age of 71 years, had a mean radiological
score of K/Lawrence of 3.8 and their pain has evolved over 7 years. Respec-
tively, moderate OA patients had 62 years, K/L score of 1,5 and 6 years
of pain. Compared to controls subjects, we found a signiﬁcant association
between the presence of a severe knee OA and serum levels of CRP (mean
8.8 vs 1.7 mg/L; p<0.001), OPG (mean 7.9 vs 5.4 ng/mL; p<0.001), MMP-3
(mean 32.4 vs 20.6 ng/mL; p<0.05) and COMP (mean 2.55 vs 2.05 μg/mL;
p<0.01). This association also exists with a low serum CTX-I (mean 0.42 vs
0.61 ng/mL; p<0.05). There was also a signiﬁcant association between the
presence of a moderate knee OA and serum levels of CRP (mean 2.6 vs 1.7
mg/L), OPG (mean 6.4 vs 5.4 ng/mL) and COMP (mean 2.43 vs 2.05 μg/mL)
(p<0,05). However, we did not ﬁnd any signiﬁcant association with low
levels of serum CTX-I or high levels of MMP-3.
Conclusions: Our results show the sensitivity of some biomarkers (bone,
cartilage or inﬂammation) to distinguish OA patients from healthy subjects.
Future work is needed to understand the pathophysiological mechanisms
involved in OA, particularly towards RANKL/OPG.
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PATHOGENESIS OF OSTEOARTHRITIS IN THE SEDC HETEROZYGOUS
MOUSE: A NEW ANIMAL MODEL
D. Holt, M. Henderson, R. Seegmiller
Brigham Young Univ., Provo, UT
Purpose: The purpose of this study was to establish the sedc heterozy-
gous (s/+) mouse as a new non-dwarfed, murine model for the study
of osteoarthritis (OA). In addition, this study was done to determine the
involvement of the HtrA-1, DDR-2 and MMP-13, known biomarkers of OA,
in the degenerative pathway of articular cartilage (AC) in the s/+ mouse
as compared to the wild-type (+/+) mouse. HtrA-1 is involved in the
destruction of the pericellular matrix surrounding chondrocytes. DDR-2 is
a cell membrane receptor protein that binds to type II collagen and triggers
the upregulation of MMP-13, which hydrolyzes type II collagen and some
proteoglycans.
Methods: The sedc heterozygote knee joint was analyzed using histological
techniques. To compare skeletal development of the s/+ mouse compared
with +/+ controls, full skeletal staining was done and 2 week growth
plates were analyzed using safranin O and fast green. Tissue sections from
mice at 2, 6, 9, 12 and 18 months of age were stained with safranin O
and fast green and analyzed with a modiﬁed Mankin scoring procedure
to compare the severity of OA in the s/+ knee joint with +/+ controls.
Immunohistochemistal (IHC) staining was used to identify the correlation
between OA and the relative upregulation of HtrA-1, DDR-2 and MMP-13.
Results: The sedc heterozygous mouse was phenotypically identical to +/+
controls in skeletal and gowth plate staining. Skeletal development was
normal, however, Mankin scoring showed a signiﬁcantly higher score in s/+
mice compared to +/+ controls at all ages. Scoring increased uniformly from
2 to 18 months. Safrinin O and fast green staining showed proteoglycan
degradation starting as early as 2 months and ﬁbrillation starting as early
as 9 months, but primarily occurring at 12 months. IHC showed that
